Management of a Type I Hypersensitivity Reaction to IV Etoposide in a Woman with a Yolk Sac Tumor: A Case Report
Type I hypersensitivity reactions to intravenous administration of etoposide are extremely rare. Etoposide is an essential component of several chemotherapy regimens used in gynecologic oncology, and discontinuation of this drug during a co...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Case Reports in Obstetrics and Gynecology |
Online Access: | http://dx.doi.org/10.1155/2011/837160 |
Summary: | Type I hypersensitivity reactions to intravenous administration of etoposide are
extremely rare. Etoposide is an essential component of several chemotherapy
regimens used in gynecologic oncology, and discontinuation of this drug during a
course of treatment should only be due to severe patient intolerance. We report
the successful use of intravenous etoposide phosphate as a substitute drug in a
patient with a yolk sac tumor who manifested a Type I hypersensitivity to
intravenous etoposide. The patient ultimately completed all 4 cycles of
bleomycin, etoposide, cisplatin (BEP) using etoposide phosphate as a substitute
drug. |
---|---|
ISSN: | 2090-6684 2090-6692 |